Welcome! Login | Register
 

The Scoop: Fung Blasts Raimondo on RI Housing, Taylor Calls McKee on Flip-Flop, and More—Welcome back to The Scoop, the 4 p.m.…

PC Men’s Basketball Picked to Finish 5th in Big East—Providence College Mens Basketball Picked to Finish 5th…

RI Foundation Begins Accepting Applications for 2015 “Genius” Grants—The Rhode Island Foundation has announced it will…

Guest MINDSETTER™ Richard Ferruccio: Cost of Incarceration vs. the Cost of Crime—In a time of difficult state budgets, questions’…

It’s All About Education: Playing in the Woods Can Help Kids Reach Their Full Potential—A couple of months ago, I wrote a…

Chef Walters Flavor + Knowledge: Pan-Seared Scallops with Arugula Pesto—Cooking scallops requires a hot pan so that…

The Scoop: Michelle Obama’s Raimondo Video Message, Gorbea’s New Ad, and More—Welcome back to The Scoop, the 4 p.m.…

Victorian Mourning Customs on Display at Hearthside this Weekend—Lincoln's Hearthside House hosts its annual exhibition on…

RI Building & Construction Trades Council to Hold Walk-a-Thon for Big Brothers Big Sisters—Rhode Island Building & Construction Trades Council will…

Report: Patriots Bolster Roster With Two Moves—Tuesday's are generally off days at Gillette Stadium.…

 
 

Kent Hospital Joins Worldwide Stroke Research

Friday, January 06, 2012

 

A medical way to halt the devastation of stroke.

Kent Hospital will join 80 hospitals worldwide in a major clinical trial that seeks to help people suffering from a stroke. This highly sophisticated study will evaluate the effectiveness of the new clot-dissolving drug Desmoteplase that may provide positive benefits to patients who have recently suffered a stroke. The advantage of Desmoteplase is that it may provide benefits up to nine hours after the onset of stroke symptoms, substantially longer than the currently used clot-dissolving drug, tissue plasminogen activator (TPA).

Stopping the damage of stroke

Most strokes are caused by a blood clot that blocks the flow of blood to the brain, depriving it of oxygen. Desmoteplase helps dissolve the clot thereby opening the blood vessel to restore blood flow. The local hub of this international trial is The Massachusetts General Hospital in Boston.

"This international multicenter ischemic stroke clinical trial evaluates the effectiveness of a new clot busting medication that can be given up to nine hours after the onset of stroke symptoms,” says Kent Hospital neurologist, Dr. S.M. Arshad Iqbal, MD. “We are excited about the potential of such treatment. If successful, a larger number of patients will be able to benefit, resulting in decreased disability from their stroke." 

Kent's leadership

“Taking part in this trial is extremely important and beneficial to the many stroke patients we see every year at Kent Hospital,” says Sandra Coletta, president and CEO of Kent Hospital. “Our participation shows the leadership we take as distinctive, 24-hour stroke center, in seeking the latest treatments to significantly improve outcomes for stroke patients.”

According to the American Heart Association/American Stroke Association, stroke is the fourth leading cause of death in the United States and the leading cause of serious, long-term disability.  On average, someone suffers a stroke every 45 seconds; someone dies of a stroke every three minutes; and nearly 800,000 people suffer a new or recurrent stroke each year.

For more health coverage, don't miss GoLocalTV, fresh every day at 4pm and on demand 24/7, here.

 

Related Articles

 

Enjoy this post? Share it with others.